Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viveve Medical Inc VIVE

Viveve Medical, Inc. designs, develops, manufactures and markets a platform medical technology, Cryogen-cooled Monopolar RadioFrequency (CMRF). The Company’s CMRF technology is delivered through a radiofrequency generator, handpiece and treatment tip, which collectively, is referred to as the Viveve System. The Viveve System is marketed for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence (SUI). In the United States, the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis. The Viveve System is cleared for marketing in approximately 48 countries throughout the world, including North America, Asia Pacific, Europe, the Middle East and Latin America countries. The Company’s wholly owned subsidiaries include Viveve, Inc. and Viveve BV.


GREY:VIVE - Post by User

Comment by dmacdon Apr 05, 2019 2:31pm
143 Views
Post# 29589138

RE:Price drops?

RE:Price drops?Great technology and development roll out. Main issue is management have been disrespectful to its shareholders with massive dilution and the cash bleed has no end in sight. Once it goes cash flow positive the SP will drive up. Losses must taper and sales cannot have slowed in Q1 after the restructure. The SP suggests investor expectations are not being achieved. If do then it will be time to replace the current team. Management should go to zero salary and 100% incentive to force alignment assuming this aspect of the company can be more competent. Let's hope for a surprise. I have too much since I bought too early. Might be a good time to buy once results are in if you are new here. The rest of the story is good.
<< Previous
Bullboard Posts
Next >>